구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | O6-Benzylguanine (O6-Benzylguanine) Keryx / AOI Pharmaceuticals, Inc.·Human Immunodeficiency Virus 1 Pos… 30 trials·t½ 5 h |
|---|---|
Overview Program | O6-Benzylguanine |
Overview Company | Keryx / AOI Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 5 h |
Toxicology Major finding | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Safety signal | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Selected reported efficacy | ORR 4% |
Clinical Reported ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT00275002 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00275002 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | O6-Benzylguanine (O6-Benzylguanine) Keryx / AOI Pharmaceuticals, Inc.·Human Immunodeficiency Virus 1 Pos… 30 trials·t½ 5 h |
|---|---|
Overview Program | O6-Benzylguanine |
Overview Company | Keryx / AOI Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 5 h |
Toxicology Major finding | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Safety signal | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Selected reported efficacy | ORR 4% |
Clinical Reported ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT00275002 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00275002 |
추천 비교
추천 비교